Exhibit 10.26

 

SECOND AMENDMENT
TO CREDIT AND SECURITY AGREEMENT

 

THIS SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this “Second Amendment”)
is made as of the 13th date of November 2013 by and among WELLS FARGO BANK,
NATIONAL ASSOCIATION (“Lender”), Albany Molecular Research, Inc., a Delaware
corporation (“AMRI” or the “Administrative Borrower”), AMRI Rensselaer, Inc., a
Delaware corporation (“AMRI Rensselaer”), AMRI Burlington, Inc., a Massachusetts
corporation (“AMRI Burlington”), and AMRI Bothell Research Center, Inc., a
Delaware corporation (“AMRI Bothell” and together with AMRI, AMRI Rensselaer and
AMRI Burlington, each a “Borrower” and collectively, the “Borrowers”).

 

WITNESSETH:

 

WHEREAS, the Borrowers and Lender are party to a certain Credit and Security
Agreement dated as of April 11, 2012, as amended by First Amendment to Credit
and Security Agreement dated as of December 20, 2012 (as the same may be further
amended, modified, supplemented or restated and in effect from time to time, the
“Credit Agreement”), pursuant to which Lender has made loans and other financial
accommodations to the Borrowers; and

 

WHEREAS, the Borrowers and Lender have agreed to enter into this Second
Amendment to modify and amend certain provisions of the Credit Agreement, but
only as provided for, and subject to the terms and conditions, herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, Lender and the Borrowers agree as follows:

 

1.           Capitalized Terms. All capitalized terms used herein and not
otherwise defined shall have the same meaning herein as in the Credit Agreement.

 

2.           Amendments to Credit Agreement. The Credit Agreement is hereby
amended as follows:

 

(a)Section 7.7(a)(i) of the Credit Agreement is hereby amended by adding the
following provision at the end of such clause: “; provided that any Loan Party
may satisfy a conversion or exchange obligation of Convertible Securities so
long as the delivery of common stock of AMRI or cash, as applicable, is
permitted by Section 7.9 hereof.”

 

(b)Section 7.9 of the Credit Agreement is hereby amended by deleting the word
“and” immediately preceding clause (e) thereof and adding the following new
clauses (f) and (g) immediately following the end of clause (e) thereof:

 

1

 

 

“(f) any Loan Party (i) may make required (A) interest payments under the
Convertible Securities or (B) principal payments either (x) in connection with a
put of Convertible Securities after the occurrence of a fundamental change (as
defined or described in such Convertible Securities), or (y) at maturity of the
Convertible Securities, (ii) may deliver common stock of AMRI in satisfaction of
all or a portion of (x) the conversion or exchange obligation in respect of any
Convertible Securities, and (y) the exercise obligations in respect of any
Warrants, in each case, so long as no Change of Control would result therefrom,
(iii) may pay cash in satisfaction of all or a portion of the conversion or
exchange obligation in respect of such Convertible Securities so long as no
Default or Event of Default has occurred or is continuing at the time of such
payment, or would be caused by such payment; provided that if any payment
described in clause (iii) hereof is paid in whole or in part with the proceeds
of any Advances, the Administrative Borrower shall have provided Lender with at
least two business days prior written notice thereof and either deposited at
least $5,000,000 in a fully blocked and segregated deposit account of a Borrower
subject to a Control Agreement, providing for sole and exclusive dominion by
Lender until all Obligations (other than inchoate indemnification obligations
for which no claim has been asserted) have been paid in full in cash and
Lender’s obligations to provide additional credit hereunder shall have been
terminated, which for the avoidance of doubt, shall be in addition to any
Borrowing Base Eligible Cash, or, if such cash collateral is not provided,
Lender shall have implemented the Availability Block prior to the Borrowers
making such payment described in clause (iii), and (iv) may purchase AMRI’s
common stock upon the exercise of the Call Options, so long as such purchase
does not involve a payment of cash by such Loan Party; and

 

(g) the issuer of any Convertible Securities may make any cash payment to
purchase Call Options out of, and substantially contemporaneously with the
receipt of, the net proceeds of the sale of Convertible Securities.”

 

(c)Section 7.12(a)(i) of the Credit Agreement is hereby amended by deleting the
figure "$500,000" therefrom and substituting therefor the figure "$1,500,000"."

 

(d)Section 7.14 of the Credit Agreement is hereby amended and restated in its
entirety as follows:

 

"Limitation on Issuance of Stock. Except for the issuance or sale of common
stock, Warrants, Convertible Securities or Permitted Preferred Stock by
Borrowers or the other Loan Parties, issue or sell or enter into any agreement
or arrangement for the issuance and sale of any of their Stock."

 

2

 

 

(e)The table in Section 8(c) of the Credit Agreement is hereby amended and
restated in its entirety as follows:

 

“Maximum Capital Expenditures   Applicable Period $6,250,000   For the 3 month
period ending March 31 in any fiscal year” $12,500,000   For the 6 month period
ending June 30 in any fiscal year” $18,750,000   For the 9 month period ending
September 30 in any fiscal year” $25,000,000   For the 12 month period ending
December 31 in any fiscal year”

 

(f)Section 8(d) of the Credit Agreement is hereby amended and restated in its
entirety as follows:

 

“(d)         [Reserved].”

 

(g)Section 8(e) of the Credit Agreement is hereby amended and restated in its
entirety as follows:

 

“(e)         Cash on Hand at Foreign Subsidiaries. The Borrowers shall not
permit their foreign Subsidiaries to hold Cash or Cash Equivalents in excess of
an aggregate average monthly amount of $10,000,000 (calculated at current
exchange rates and tested as of the close of business of the last Business Day
of month).”

 

(h)Section 9.7 of the Credit Agreement is hereby amended by inserting “or (c) a
fundamental change (as defined or described in any Convertible Securities” after
clause (b) therein.

 

(i)Schedule 1.1 to the Credit Agreement is hereby amended as follows:

 

(i)The definition of “Borrowing Base” is hereby amended and restated in its
entirety as follows:

 

““Borrowing Base” means as of any date of determination, the result of:

 

3

 

 

(a)         85% of the Eligible Royalties Receivable accrued on the Borrowers’
books and records in accordance with GAAP (less the amount, if any, of the
Dilution Reserve, if applicable), plus

 

(b)         the M&E Sublimit, plus

 

(c)         the lesser of (i) $5,000,000 and (ii) the amount of Borrowing Base
Eligible Cash, minus

 

(d)         the Availability Block, minus

 

(e)         the aggregate amount of Reserves, if any, established by Lender.”

 

(ii)The definition of “EBITDA” is hereby amended by (A) adding “without
duplication” prior to the colon in clause (b) thereof, (B) deleting the word
“and” at the end of clause (b)(iii) thereof, and (C) adding the following new
clause (b)(v) thereto: “and (v) the net cash proceeds of any Fundamental Change
Put Financing”.

 

(iii)The definition of “Eligible Royalties Receivable” is hereby amended and
restated in its entirety as follows:

 

“Eligible Royalties Receivables” means the royalties receivables from the
Sanofi-Aventis License Agreement or the Actavis Development and Supply Agreement
that are not excluded as ineligible by one or more of the excluding criteria set
forth below; provided, however, that such criteria may be revised from time to
time by Lender in Lender’s Permitted Discretion. Eligible Royalties Receivables
shall not include the following:

 

(a)         royalty receivables from the Sanofi-Aventis License Agreement or the
Actavis Development and Supply Agreement received by a Borrower more than 65
days after the end of each fiscal quarter;

 

(b)         at Lender’s option, all or any portion of the royalty receivables
from either the Sanofi-Aventis License Agreement or the Actavis Development and
Supply Agreement if 10% or more of the aggregate amount of royalty receivables
payable under such agreement and due after the end of any fiscal quarter are
deemed ineligible under clause (a) above;

 

(c)         all of the royalty receivables from the Sanofi-Aventis License
Agreement if Aventis Pharmaceuticals, Inc. (or its successors or assigns) is
subject to an Insolvency Proceeding, is not Solvent, has gone out of business,
or as to which a Borrower has received notice of an imminent Insolvency
Proceeding or a material impairment of the financial condition of such Person;
or all of the royalty receivables from the Actavis Development and Supply
Agreement if Actavis, Inc. (or its successors or assigns) is subject to an
Insolvency Proceeding, is not Solvent, has gone out of business, or as to which
a Borrower has received notice of an imminent Insolvency Proceeding or a
material impairment of the financial condition of such Person; or

 

4

 

 

(d)         all of the royalty receivables from the Sanofi-Aventis License
Agreement and/or the Actavis Development and Supply Agreement, the collection of
either of which, Lender, in its Permitted Discretion, believes to be doubtful by
reason of either Aventis Pharmaceuticals, Inc.’s or Actavis Inc.’s (or its
successors or assigns) financial condition.

 

Any royalty receivables from the Sanofi-Aventis License Agreement or the Actavis
Development and Supply Agreement which are not Eligible Royalties Receivables
shall nonetheless constitute Collateral.”

 

(iv)The definition of “Hedge Agreement” is hereby amended and restated in its
entirety as follows:

 

“Hedge Agreement” means a “swap agreement” as that term is defined in Section
101(53B)(A) of the Bankruptcy Code, other than any Call Options or Warrants.

 

(v)The following sentence shall be added to the end of the definition of
“Indebtedness”: “Notwithstanding the foregoing, and for the avoidance of doubt,
any Warrants shall not constitute Indebtedness.”

 

(vi)The following sentence shall be added to the end of the definition of
“Investment”: “Notwithstanding the foregoing, and for the avoidance of doubt,
any Call Options shall not constitute an Investment to the extent that such Call
Options provide that no cash payments (other than the initial purchase thereof
in accordance with Section 7.9(g) of this Agreement) shall be payable by any
Loan Party in connection therewith.”

 

(vii)The definition of “Permitted Indebtedness” is hereby amended by deleting
the word “and” immediately preceding clause (h) thereof and adding the following
new clauses (i) and (j) immediately following the end of clause (h) thereof:

 

“(i) Indebtedness consisting of Convertible Securities; and

 

(j) Indebtedness consisting Fundamental Change Put Financing.”

 

(viii)The following new definitions are hereby added to Schedule 1.1 in the
appropriate alphabetical order:

 

5

 

 

““Availability Block” means either $0.00 or if the Borrowers have not provided
the cash collateral described in Section 7.9(f)(iii), $5,000,000.”

 

““Actavis Development and Supply Agreement” means the Development and Supply
Agreement by and between Organichem Corp (now AMRI) and Purepac Pharmaceutical
Co. (now Actavis US) dated May 10, 2000, as amended prior to October 31, 2012.”

 

““Call Options” means, with respect to any Convertible Securities, any options
to purchase common stock of AMRI (regardless of whether settled in cash or such
common stock or any combination thereof) that are purchased by AMRI, or any
other Borrower issuing such Convertible Securities, substantially
contemporaneously with the sale of such Convertible Securities.”

 

““Convertible Securities” means any Indebtedness of AMRI or any other Borrower
that is convertible, or exchangeable, at the option of the holders thereof into
cash, shares of AMRI’s common stock or any combination thereof and any guarantee
in respect thereof , so long as (a) the scheduled maturity thereof is on or
after the date that is four years, ten months after the first date of original
issuance thereof, (b) the aggregate principal amount of such Convertible
Securities (including any issuance upon exercise of any underwriter’s or initial
purchaser’s option) shall not exceed $150,000,000, (c) there is no sinking fund
or any scheduled payment of principal prior to such date, and (d) the interest
rate on such Indebtedness shall not exceed 5.0% per annum.”

 

““Fundamental Change Put Financing” means any Indebtedness of AMRI or any other
Borrower, substantially all of the Net Cash Proceeds of which are used to
satisfy AMRI’s obligations to purchase the Convertible Securities upon a
fundamental change (as defined or described in such Convertible Securities).”

 

““Warrants” means, with respect to any Convertible Securities, any warrants to
purchase common stock of AMRI that are issued by AMRI substantially
contemporaneously with the sale of such Convertible Securities.”

 

3.             Ratification of Loan Documents. Except as specifically amended by
this Second Amendment, all of the terms and conditions of the Credit Agreement
and of each of the other Loan Documents shall remain in full force and effect.
Each of the Loan Parties hereby ratifies, confirms, and reaffirms all of the
representations, warranties and covenants contained in the Credit Agreement or
any other Loan Document. The Loan Parties warrant and represent that no Event of
Default exists before or after giving effect to this Second Amendment. Each of
the Loan Parties hereby acknowledges and agrees that it has no offsets,
defenses, claims, or counterclaims against Lender with respect to the
Obligations, or otherwise, and that if such Loan Party now has, or ever did
have, any offsets, defenses, claims, or counterclaims against Lender, whether
known or unknown, at law or in equity, all of them are hereby expressly waived
and such Loan Party hereby releases Lender from any liability thereunder.

 

6

 

 

 

4.             Waiver. Each Loan Party hereby absolutely and unconditionally
releases and forever discharges Lender, and any and all participants, parent
corporations, subsidiary corporations, affiliated corporations, insurers,
indemnitors, successors and assigns thereof, together with all of the present
and former directors, officers, agents and employees of any of the foregoing,
from any and all claims, demands or causes of action of any kind, nature or
description, whether arising in law or equity or upon contract or tort or under
any state or federal law or otherwise, which such Loan Party has had, now has or
has made claim to have against any such person for or by reason of any act,
omission, matter, cause or thing whatsoever arising from the beginning of time
to and including the date of this Second Amendment, whether such claims, demands
and causes of action are matured or unmatured or known or unknown.

 

5.             Conditions to Effectiveness. This Second Amendment shall become
effective on the date hereof (“Second Amendment Effective Date”) only upon
satisfaction of each of the following conditions to the satisfaction of Lender:

 

(a)This Second Amendment shall have been duly executed and delivered by the
respective parties hereto and shall be in form and substance satisfactory to
Lender.

 

(b)All corporate and shareholder action on the part of each Loan Party necessary
for the valid execution, delivery and performance of this Second Amendment shall
have been duly and effectively taken and evidence thereof satisfactory to Lender
shall have been provided to Lender.

 

(c)No Default or Event of Default shall have occurred and be continuing.

 

(d)There shall be no material misstatements in the materials furnished by the
Loan Parties to Lender prior to closing of this Second Amendment, or in
representations or warranties of the Loan Parties made in the Credit Agreement.
Lender shall be satisfied that any financial statements of the Loan Parties
delivered to it by the Loan Parties fairly present in all material respects the
financial condition of the Loan Parties and that there has been no material
adverse change in the assets, business, financial condition or income of the
Loan Parties since the date of the most recent financial statements of the Loan
Parties delivered to Lender pursuant to Section 6.1 of the Credit Agreement.

 

(e)The Loan Parties shall have paid to Lender all costs and expenses of Lender
(including, without limitation, reasonable attorneys’ fees) in connection with
the preparation, negotiation, execution and delivery of this Second Amendment.

 

7

 

 

 

(f)The Loan Parties shall have paid to Lender a one-time amendment fee of
$50,000 which shall be fully earned and payable upon the execution of this
Second Amendment and shall not be subject to refund or rebate under any
circumstances.

 

6.           Miscellaneous.

 

(a)This Second Amendment may be executed in several counterparts and by each
party on a separate counterpart, each of which when so executed and delivered
shall be an original, and all of which together shall constitute one instrument.
Delivery of an executed counterpart by facsimile or other electronic
transmission shall be equally as effective as delivery of an original executed
counterpart hereof.

 

(b)This Second Amendment expresses the entire understanding of the parties with
respect to the transactions contemplated hereby. No prior negotiations or
discussions shall limit, modify, or otherwise affect the provisions hereof.

 

(c)Any determination that any provision of this Second Amendment or any
application hereof is invalid, illegal or unenforceable in any respect and in
any instance shall not affect the validity, legality, or enforceability of such
provision in any other instance, or the validity, legality or enforceability of
any other provisions of this Second Amendment.

 

(d)The Loan Parties represent and warrant that they have consulted with
independent or internal legal counsel of their selection in connection with this
Second Amendment and are not relying on any representations or warranties of
Lender or its counsel in entering into this Second Amendment.

 

(e)THE VALIDITY, INTERPRETATION AND ENFORCEMENT OF THIS SECOND AMENDMENT AND ANY
DISPUTE ARISING OUT OF THE RELATIONSHIP BETWEEN THE PARTIES HERETO, WHETHER IN
CONTRACT, TORT, EQUITY OR OTHERWISE, SHALL BE GOVERNED BY THE INTERNAL LAWS OF
STATE OF NEW YORK.

 

[SIGNATURE PAGES FOLLOW]

 

8

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amendment as a sealed
instrument by their respective duly authorized officers.

 

BORROWERS: ALBANY MOLECULAR RESEARCH, INC.       By: /s/ Michael M. Nolan  
Name: Michael M. Nolan   Title: Vice President & CFO       AMRI RENSSELLAER,
INC.       By: /s/ Michael M. Nolan   Name: Michael M. Nolan   Title: Treasurer
      AMRI BURLINGTON, INC.       By: /s/ Michael M. Nolan   Name: Michael M.
Nolan   Title: Vice President & CFO       AMRI BOTHELL RESEARCH, INC.       By:
/s/ Michael M. Nolan   Name: Michael M. Nolan   Title: Vice President & CFO

 

 

 

 

LENDER: WELLS FARGO BANK, NATIONAL ASSOCIATION       By: /s/ Patricia Farrell  
Name: Patricia Farrell   Title: Vice President